Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ADGI

Adagio Therapeutics (ADGI) Stock Price, News & Analysis

Adagio Therapeutics logo

About Adagio Therapeutics Stock (NASDAQ:ADGI)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$3.40
$4.78
52-Week Range
N/A
Volume
22,357 shs
Average Volume
2.27 million shs
Market Capitalization
$504.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Remove Ads
Receive ADGI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adagio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ADGI Stock News Headlines

Our Favorite Advent Calendars
Trump’s Secret Weapon
Please don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your free gift, and see how Trump's victory could spark major gains for gold.
See More Headlines

ADGI Stock Analysis - Frequently Asked Questions

Adagio Therapeutics, Inc. (NASDAQ:ADGI) announced its quarterly earnings data on Sunday, November, 14th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by $0.24.

Adagio Therapeutics (ADGI) raised $301 million in an initial public offering on Friday, August 6th 2021. The company issued 17,700,000 shares at a price of $16.00-$18.00 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that Adagio Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Pfizer (PFE), PayPal (PYPL), Tesla (TSLA), AbbVie (ABBV) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
11/14/2021
Today
4/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ADGI
Fax
N/A
Employees
2,021
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-226,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$5.02 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$504.98 million
Optionable
Not Optionable
Beta
N/A
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:ADGI) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners